Home › Research › Biomarkers
Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal
Vermunt L, van Paasen AJL, Teunissen CE, Scheltens P, Visser PJ, Tijms BM, Alzheimer's Disease Neuroimaging Initiative.. Neurology, 2019-05-08
Topic: Amyloid, tau and blood-test diagnosis
Objective To identify potential predictors for outcome in individuals with mild cognitive impairment (MCI) who have reverted to normal cognition (NC). Methods We selected individuals with MCI, who reverted at follow-up to NC, with follow-up after reversion from Alzheimer's Disease Neuroimaging Initiative. Common clinical markers, Alzheimer disease (AD) biomarkers, and neurodegeneration imaging markers were used to compare MCI reverters based on subsequent clinical outcome (i.e., subsequent decline or stable reversion). For independent comparison, findings of the clinical Amsterdam Dementia Cohort are presented. Results Seventy-seven (10%) out of 757 individuals with MCI reverted to NC and 61 of these individuals had follow-up data available. After 3.2 ± 2.2 years, 16 (24%) progressed to MCI, and 3 (5%) to dementia. Those who declined were older and had a higher amyloid PET burden and higher CSF tau levels. Conclusion In MCI reverters, abnormal biomarkers for AD pathology are associated with subsequent decline. AD biomarkers may aid in the prognosis of reverting MCI.
Key findings
- Results Seventy-seven (10%) out of 757 individuals with MCI reverted to NC and 61 of these individuals had follow-up data available.
- Conclusion In MCI reverters, abnormal biomarkers for AD pathology are associated with subsequent decline.
Why it matters
Among 61 people with mild cognitive impairment who reverted to normal cognition, those who later declined were older and had higher amyloid PET burden and higher CSF tau levels. This is about using biomarkers to predict outcome after reversion, not about treating, curing or preventing Alzheimer's disease.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants757
- Evidence strengthModerate
How this study scored 48/100
Published in a leading specialty journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 46 of the 96 points we could judge it on, which is 48 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2019 — within 10 year(s) of the newest study here |
| Sample size | 2 / 4 | 757 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 14 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.6 citations a year over 9 year(s) since 2019 |
| Impact for its field and year | 2 / 6 | Cited 1.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 4 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 1 / 3 | Vrije Universiteit Amsterdam: institution h-index 1,014 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 31068481) |
| Free to read | 2 / 2 | Free to read |
| Points | 46 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 46 of the 96 points we could judge it on is 48 out of 100. |
| Total | 48 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
APA 7th
Vermunt, L., van Paasen, A. J. L., Teunissen, C. E., Scheltens, P., Visser, P. J., Tijms, B. M., et al. (2019). Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal. Neurology. https://doi.org/10.1212/wnl.0000000000007609
Vancouver
Vermunt L, van Paasen AJL, Teunissen CE, Scheltens P, Visser PJ, Tijms BM, et al. Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal. Neurology. 2019. doi:10.1212/wnl.0000000000007609. PMID: 31068481.
BibTeX
@article{vermunt2019-31068481,
author = {Vermunt, L. and van Paasen, A. J. L. and Teunissen, C. E. and Scheltens, P. and Visser, P. J. and Tijms, B. M. and {Alzheimer's Disease Neuroimaging Initiative}},
title = {{Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal}},
journal = {Neurology},
year = {2019},
doi = {10.1212/wnl.0000000000007609},
pmid = {31068481},
url = {https://doi.org/10.1212/wnl.0000000000007609}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Biomarkers
Also tagged “biomarkers”
821 studies in the library carry the topic tag “biomarkers”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 821 tagged studies.